Ascendis Pharma (NASDAQ: ASND) brokered sale of 10,800 shares planned

Rhea-AI Filing Summary

Ascendis Pharma A/S submitted a Form 144 disclosing the proposed sale of 10,800 ordinary shares through Citigroup Global Markets on 03/02/2026. The filing also records restricted stock vesting of 18,349 shares as compensation on 03/02/2026 and prior sales of 10,000 shares on 12/02/2025 for 2093222.47.

Insights

Corporate Governance Analyst

Form 144 discloses planned brokered sale and recent insider vesting and prior sale.

The filing lists a proposed broker-facilitated sale of 10,800 ordinary shares via Citigroup Global Markets dated 03/02/2026. It separately records restricted stock vesting of 18,349 shares as compensation on the same date.

Prior disposition of 10,000 shares on 12/02/2025 for 2093222.47 is shown. The document is a notice of intent to sell; actual sale timing and cash‑flow recipients depend on subsequent transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	10800	2614572.00	61977408	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/02/2026	RESTRICTED STOCK VESTING	ASCENDIS PHARMA A/S			18349	03/02/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KENNETT SPROGOE TUBORG BOULEVARD 12 HELLERUP G7 DK2900	ORDINARY SHARES	12/02/2025	10000	2093222.47

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ascendis Pharma (ASND) Form 144 disclose about shares to be sold?

The filing discloses a proposed sale of 10,800 ordinary shares through Citigroup Global Markets on 03/02/2026, showing the broker, share count, and sale date as reported.

Did the Form 144 report any vested compensation for ASND?

Yes. The filing records restricted stock vesting of 18,349 shares attributable to compensation on 03/02/2026, listed separately from the brokered sale intent.

Were there recent insider sales reported in the Form 144 for ASND?

The document shows a prior sale of 10,000 ordinary shares on 12/02/2025 with proceeds of 2093222.47, reported in the “Securities Sold During The Past 3 Months” section.

Which broker is handling the proposed ASND sale in the Form 144?

The proposed sale is listed as being handled by Citigroup Global Markets at 390 Greenwich St, New York, NY, associated with the 03/02/2026 transaction row.